The opera project email format

Artificial intelligence (AI) is expected to personalise treatment of colorectal cancer and reduce the incidence and mortality rates. This is the aim of the EU-funded OperA project. We are conducting a pan-European, population-based, randomised trial to establish the value of AI-assisted colonoscopy in colorectal cancer prevention. Overall, the project's goal is to drastically improve colorectal cancer care. The OperA project will also produce a risk-prediction tool for personalised treatment and cost-effective models of AI-assisted colonoscopy in colorectal cancer screening. OperA will also address the ethical and legal barriers to AI development and implementation. Beneficiaries and Associate Partners - (Lead) University of Oslo, Norway (Yuichi Mori) Oslo University Hospital, Norway (Michael Bretthauer) MAGIC Evidence Ecosystem Foundation, Norway (Per Olav Vandvik) Aarhus University, Denmark (Rune Erichsen) Karolinska Institute, Sweden (Hans Olov Adami) Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland (Michal F. Kaminski) Fundació Clínic per a la Recerca Biomèdica and Hospital Clinic de Barcelona, Spain (María Pellisé) Humanitas University, Italy (Cesare Hassan) University Hospital Eppendorf, Germany (Thomas Rosch) National and Kapodistrian University of Athens, Greece (Konstantinos Triantafyllou) King's College Hospital NHS Foundation Trust, UK (Shraddha Gulati) University College London, United Kingdom (Omer Ahmad) Maplesoft Europe Limited, United King (Juergen Gerhard) Beth Israel Deaconess Medical Center, INC Non-profit Corporation, USA (Tyler M Berzin) The Pennsylvania State University, USA (Sara Gerke) Showa University, Japan (Shin-ei Kudo) Nagoya University, Japan (Kensaku Mori)